B+
Bull case
24%
Probability
Target price
$28.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
SRPT
Sarepta TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
52%
Probability
Target price
$22.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
24%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-17
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+67.9
Score
AI commentary
Recent coverage is mixed: Q2 profitability, pipeline milestones, and regulatory progress are constructive, while ELEVIDYS weakness and narrowed guidance are negative. Social, options, short-interest, employee-rating, and verified post-release price-reaction data are unavailable; low coverage and broad peers limit confidence. [#SEC-8K-2026-08-05] [#PR-EARNINGS-2026-08-13]
RankAlpha Sentiment Codex - 2026-08-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-17catalystQ2 profitability offsets mixed commercial signalHigh impact
Q2 2026 net product revenue was $328.7 million, with GAAP and non-GAAP operating income of $13.3 million and $86.5 million. Profitability is constructive, but ELEVIDYS weakness and narrowed full-year product guidance leave near-term sentiment mixed. [#SEC-8K-2026-08-05]
2026-12-31catalystDM1 and FSHD siRNA clinical readoutsHigh impact
MAD-cohort readouts from Phase 1/2 DM1 and FSHD studies remain on track for the second half of 2026. Early exposure and biomarker signals are encouraging, but efficacy and durability remain unproven. [#SEC-8K-2026-08-05]
2027-02-28eventPotential traditional-approval decisions for AMONDYS 45 and VYONDYS 53High impact
The FDA accepted supplemental applications seeking conversion of AMONDYS 45 and VYONDYS 53 from accelerated to traditional approval. The outcome is binary; stored earnings context indicates a potential decision window around February 2027. [#SEC-8K-2026-08-05] [#PR-EARNINGS-2026-08-13]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-17 • Updated nightlySource: Internal modelMethodology